Literature DB >> 12960213

Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries.

H P H Neumann1, M Salzmann, B Bohnert-Iwan, T Mannuelian, C Skerka, D Lenk, B U Bender, M Cybulla, P Riegler, A Königsrainer, U Neyer, A Bock, U Widmer, D A Male, G Franke, P F Zipfel.   

Abstract

BACKGROUND: The aetiology of atypical haemolytic uraemic syndrome (aHUS) is, in contrast to classical, Shiga-like toxin induced HUS in children, largely unknown. Deficiency of human complement factor H and familial occurrence led to identification of the factor H gene (FH1) as the susceptibility gene, but the frequency and relevance of FH1 mutations are unknown.
METHODS: We established a German registry for aHUS and analysed in all patients and 100 controls the complete FH1 gene by single strand confirmational polymorphism and DNA sequencing. In addition, complement C3 and factor H serum levels were assayed. Demographic data at onset of aHUS and follow up were compared for the mutation positive and negative groups.
RESULTS: Of 111 patients with aHUS (68 female, 43 male, mean age 33 years) 14% had FH1 germline mutations, including two of eight patients with familial aHUS. For each of these eight patients, both parents were tested, and we were able to trace the mutation for five cases. In the other three cases (one with the mutation 3749 C/T, one with 3200 T/C, and one with 3566+1 G/A), we could not detect the mutation in either parent, although paternity was proven by genetic fingerprinting, suggesting that these subjects have new mutations. C3 was decreased in five mutation carriers but also in two non-carriers, and factor H was decreased in none of the carriers, but elevated in six carriers and 15 non-carriers. Clinical parameters including associated medications and diseases, and outcome of aHUS and of post-aHUS kidney transplantation were similar in the mutation positive and negative groups.
CONCLUSION: FH1 germline mutations occur with considerable frequency in patients with aHUS. Hypocomplementaemia is not regularly associated with a germline mutation, and factor H serum levels can even be elevated. Screening for FH1 mutations contributes to the classification of aHUS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960213      PMCID: PMC1735586          DOI: 10.1136/jmg.40.9.676

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  35 in total

Review 1.  FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function.

Authors:  P F Zipfel; C Skerka
Journal:  Immunol Today       Date:  1999-03

2.  Complement factor H and the haemolytic uraemic syndrome.

Authors:  C M Taylor
Journal:  Lancet       Date:  2001-10-13       Impact factor: 79.321

3.  Combined kidney and liver transplantation for familial haemolytic uraemic syndrome.

Authors:  Giuseppe Remuzzi; Piero Ruggenenti; Daniela Codazzi; Marina Noris; Jessica Caprioli; Giuseppe Locatelli; Bruno Gridelli
Journal:  Lancet       Date:  2002-05-11       Impact factor: 79.321

4.  Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA).

Authors:  M A Friese; J Hellwage; T S Jokiranta; S Meri; H J Müller-Quernheim; H H Peter; H Eibel; P F Zipfel
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

5.  The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.

Authors:  Jessica Caprioli; Paola Bettinaglio; Peter F Zipfel; Barbara Amadei; Erica Daina; Sara Gamba; Christine Skerka; Nicola Marziliano; Giuseppe Remuzzi; Marina Noris
Journal:  J Am Soc Nephrol       Date:  2001-02       Impact factor: 10.121

6.  Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome.

Authors:  L Ying; Y Katz; M Schlesinger; R Carmi; H Shalev; N Haider; G Beck; V C Sheffield; D Landau
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

Review 7.  Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

Authors:  P Ruggenenti; M Noris; G Remuzzi
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

8.  Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding site.

Authors:  Stephen J Perkins; Timothy H J Goodship
Journal:  J Mol Biol       Date:  2002-02-15       Impact factor: 5.469

9.  Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome.

Authors:  D Pérez-Caballero; C González-Rubio; M E Gallardo; M Vera; M López-Trascasa; S Rodríguez de Córdoba; P Sánchez-Corral
Journal:  Am J Hum Genet       Date:  2001-01-17       Impact factor: 11.025

10.  Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition.

Authors:  A Richards; M R Buddles; R L Donne; B S Kaplan; E Kirk; M C Venning; C L Tielemans; J A Goodship; T H Goodship
Journal:  Am J Hum Genet       Date:  2001-01-17       Impact factor: 11.025

View more
  66 in total

Review 1.  Exploring the genetic basis of early-onset chronic kidney disease.

Authors:  Asaf Vivante; Friedhelm Hildebrandt
Journal:  Nat Rev Nephrol       Date:  2016-01-11       Impact factor: 28.314

2.  The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein.

Authors:  M Oppermann; T Manuelian; M Józsi; E Brandt; T S Jokiranta; S Heinen; S Meri; C Skerka; O Götze; P F Zipfel
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

3.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

Review 4.  Living donor kidney transplantation in patients with hereditary nephropathies.

Authors:  Patrick Niaudet
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

5.  Personalized medicine in chronic kidney disease by detection of monogenic mutations.

Authors:  Dervla M Connaughton; Friedhelm Hildebrandt
Journal:  Nephrol Dial Transplant       Date:  2020-03-01       Impact factor: 5.992

6.  A case of atypical hemolytic uremic syndrome with a transient decrease in complement factor H.

Authors:  Hyewon Hahn; Eun Young Um; Young Seo Park; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2005-12-17       Impact factor: 3.714

Review 7.  What's new in haemolytic uraemic syndrome?

Authors:  Sally Johnson; C Mark Taylor
Journal:  Eur J Pediatr       Date:  2008-06-25       Impact factor: 3.183

8.  Eculizumab cessation in atypical hemolytic uremic syndrome.

Authors:  Samuel A Merrill; Zachary D Brittingham; Xuan Yuan; Alison R Moliterno; C John Sperati; Robert A Brodsky
Journal:  Blood       Date:  2017-05-01       Impact factor: 22.113

Review 9.  Advances and challenges in the management of complement-mediated thrombotic microangiopathies.

Authors:  Jean-Claude Davin; Nicole C A J van de Kar
Journal:  Ther Adv Hematol       Date:  2015-08

Review 10.  Genetics and complement in atypical HUS.

Authors:  David Kavanagh; Tim Goodship
Journal:  Pediatr Nephrol       Date:  2010-06-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.